Serratiopeptidase

Brands of Serratiopeptidase in Kenya

Emanzen Forte,Emcure Pharmaceuticals Ltd


Serratiopeptidase in kenya
Serratiopeptidase

MODE OF ACTION:

Serratiopeptidase reduces pain and swelling without inhibiting prostaglandins and has no gastrointestinal adverse effects. It also acts by enhancing blood circulation due to proteolytic effect, removing damaged and denatured proteins and cellular debris, and modulating inflammatory cytokines.

INDICATIONS

Facial swelling after surgery to clear the sinuses.

Insufficient Evidence for

Chronic bronchitis. Developing research suggests that serrapeptase can significantly reduce coughing and thin secretions in people with chronic bronchitis after about 4 weeks of treatment.
Sinus pain (sinusitis). Early research suggests that people with sinusitis who take serrapeptase have significantly reduced pain, nasal secretions, and nasal obstruction after 3-4 days of treatment.
Hoarseness (laryngitis). Early research suggests that serrapeptase can significantly reduce pain, secretions, difficulty swallowing, and fever in people with laryngitis after 3-4 days of treatment.
Sore throat (pharyngitis). Early research suggests that serrapeptase can significantly reduce pain, secretions, difficulty swallowing, and fever in people with sore throat after 3-4 days of treatment.
Back pain.
Osteoarthritis.
Rheumatoid arthritis.
Osteoporosis.
Carpel tunnel syndrome.
Diabetes.
Leg ulcers.
Migraine headache.
Tension headache.
Asthma.
Pus accumulation (empyema).
Thrombophlebitis.
Fibromyalgia.
Fibrocystic breast disease.
Inflammatory bowel disease (IBD) including ulcerative colitis and Crohn’s disease.
Breast engorgement.
Heart disease.
Ear infections.

DOSAGE AND ADMINISTRATION

The usual adult dosage of serrapeptase is 10 mg 3 times daily (range, 15 to 60 mg/day) 2 hours after meals. Serrapeptase has been taken for 1 to 2 weeks as an anti-inflammatory agent and up to 4 weeks as a mucolytic agent.

CONTRAINDICATIONS:

None known.

DRUG INTERACTIONS:

Serrapeptase might decrease blood clotting. Therefore, taking serrapeptase along with medications that also slow clotting might increase the chances of bruising and bleeding.

ADVERSE EFFECTS

Serrapeptase was well tolerated in short-term clinical trials, but long-term safety has not been evaluated. Rare, serious adverse effects reported with serrapeptase include eosinophilic pneumonitis, bullous pemphigoid, hemorrhage in a patient with Behcet disease, and possibly Stevens-Johnson syndrome.

Reporting of suspected adverse reactions:

The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, pv@pharmacyboardkenya.org or clicking below button:


where to buy serrapeptase in nairobi
how much is serrapeptase in kenya
Serratiopeptidase in Kenya
Serratiopeptidase in Kenya
Serratiopeptidase in Kenya

Clinical | Pharmacokinetic data


Pregnancy Category:
Routes of Administration: Oral
Bioavailability: Not Available
Protein Binding:
Metabolosim:
Onset of Action:
Elimination Half life:
Excretion:

Legal Status | Dosage forms & Strengths


Prescription Category:

Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:

Dosage Forms | Strengths:


Drug Indentifiers:

EC number3.4.24.40
CAS number70851-98-8


Drug Images

References/ Citation:

Side Effect


Suspected health product

At the time of the side effect, specify:

%d bloggers like this: